IL17A and COVID-19: Previous studies showed an association of IL-17A salivary levels with COVID-19 severity (14), as well as an imbalance in the Th17/Treg axis (26), leading to the suggestion that an IL-17A blockade could constitute a viable therapeutic strategy (27, 28).